MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Friday, April 22, 2011

The Majority of Surveyed U.S. Neurologists Selected Tysabri as the Most Effective Therapy for the Treatment of Relapsing-Remitting Multiple Sclerosis


The Majority of Surveyed U.S. Neurologists Selected Tysabri as the Most Effective Therapy for the Treatment of Relapsing-Remitting Multiple Sclerosis, When Compared to Other Currently Available Agents

April 21, 2011
However, No Surveyed MCO Pharmacy Directors Chose Tysabri as the Most Efficacious Agent for the Indication, According to Findings from Decision Resources
BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of surveyed U.S. neurologists (63 percent) selected Biogen Idec/Elan’s Tysabri as the most effective therapy for the treatment of relapsing-remitting multiple sclerosis, when compared to other currently available agents. However, no surveyed managed care organizations’ (MCO) pharmacy directors chose Tysabri as the most efficacious available agent for the indication.
Decision Resources’ analysis of the multiple sclerosis drug market reveals that surveyed neurologists’ overwhelming response is consistent with the perception among interviewed experts that Tysabri is the most effective therapy for relapsing-remitting multiple sclerosis—a view supported by clinical studies and clinical experience that suggest the drug’s efficacy is superior to other current agents. Surveyed neurologists indicate a high level of satisfaction with Tysabri’s efficacy, more specifically its impact on relapses (which is sizable compared with other current therapies), disability progression and lesions.

CLICK HERE to continue


****************************************************************
Remain CURRENT with Multiple Sclerosis information 
 when registered at the  MS Views and News  website
.
***************************************************************************************
Help to Educate:  Please donate   - all contributions are tax deductible - 
.
"Providing You with 'MS Views and News'is what we do"
***************************************************************************************
.
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
.
 ****************************************************************

No comments: